• 목록

READYCURE and CUREVERSE Sign MOU for 

Technical and Business Collaboration

Joint project to develop an optimized intracerebral drug delivery system based on digital X-ray technology

A major milestone toward an innovative convergence model of medical devices and new drugs

The first case demonstrating the potential of digital X-ray as a platform technology to enhance drug efficacy

On April 18, READYCURE Inc. (CEO: Weon Kuu Chung), a company developing digital X-ray treatment systems 

for dementia, announced that it had signed a Memorandum of Understanding (MOU) with CUREVERSE Inc. 

(CEO: Sungjin Cho), a company specializing in treatments for dementia and neurological disorders.

This MOU aims to carry out a joint project for the development of an optimized intracerebral 

drug delivery system using digital X-ray technology,

combining READY CURE’s multimodal action technology of digital X-ray with CUREVERSE’s 

innovative new drug clinical pipeline, to jointly develop an optimal drug delivery system 

(tentatively named EPATA) for blood-brain barrier modulation and restoration of the intracerebral microenvironment,

ultimately contributing to the advancement of the healthcare industry and improvement of human health.

In this collaboration, READY CURE will provide technologies to enhance drug absorption and 

efficacy by utilizing the biological mechanisms of digital X-rays,

and will lead the R&D on optimal X-ray application conditions and mechanism analysis.

CUREVERSE will contribute by evaluating the efficacy of its new drug candidate CV-01, 

which targets the Keap1/Nrf2 signaling pathway for refractory neurological diseases,

and will advance clinical development and efficacy testing within the X-ray delivery platform.

READY CURE, leading this collaboration, is a company specializing in digital X-ray and AI-integrated medical devices.

It is currently developing HeLaXON, a digital X-ray treatment system for Alzheimer's disease that utilizes low-dose, 

low-energy, pulsed X-ray sources based on carbon nanotubes. 

In June 2024, the company was selected for the Deep Tech TIPS program by the Ministry of SMEs and Startups,

accelerating the advancement of its R&D efforts,

and enhancing the completeness and scalability of its platform technology.

READY CURE has demonstrated, through multiple preclinical studies, 

that its technology supports anti-inflammatory action, neuroprotection, Aβ/tau protein clearance, 

and BBB integrity improvement, validating the multimodal effects of low-dose X-rays. 

In the world's largest clinical study for early-stage Alzheimer’s patients,

significant improvements in cognitive function and reductions in amyloid accumulation 

(confirmed via amyloid PET imaging) were observed compared to the control group.

Based on these results, READY CURE is proposing a fundamental treatment approach for 

refractory neurodegenerative diseases and is establishing an innovative platform using 

digital X-ray technology. Through the HeLaXON system, 

it aims to provide not only AI-based dementia diagnosis and prognosis,

but also a comprehensive treatment platform for dementia, and is dedicated to 

technology development and clinical validation.

READY CURE is currently preparing for pivotal clinical trials and global market entry, 

starting with participation in CES 2025 and collaboration with Paragon Care in Australia,

and is expanding its partnerships with leading domestic and international companies, hospitals, 

and research institutes. CUREVERSE, collaborating in this project, is a biotech company that leverages 

proprietary small-molecule drug discovery technologies

to develop therapies for refractory and chronic diseases. Focusing on unmet medical needs, 

it applies the ‘Right Structure’ design philosophy

and builds strong preclinical data to enhance the success rates of its new drug candidates.

Its key pipeline, CV-01, targets conditions such as Alzheimer’s and Parkinson’s diseases,

and is currently undergoing a Phase 1 clinical trial at Seoul National University Hospital to evaluate its safety.

In October of last year, CUREVERSE signed a technology transfer deal worth approximately KRW 500 billion 

with Angelini Pharma of Italy, laying the foundation for global commercialization and actively pursuing 

new indications through partnerships and R&D.

Weon Kuu Chung, CEO of READY CURE, stated, “This MOU marks more than a joint study; it will become 

a pivotal moment in presenting a convergence model of medical devices and new drugs,

Especially since this is the first case showcasing digital X-ray as a platform technology to enhance drug efficacy,

it is expected to become a powerful synergy model with potential for expansion to various indications.”